Go to Contents
ABOUT US
Company History
Contact Us
PIPELINE
Development Pipeline
BAL0891
SJ-600 Series
Pexa-Vec(JX-594)
JX-900 Series
TECHNOLOGY
GEEV ®
SOLVE ®
Scientific Publications
PARTNERSHIP
Global
Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
Sillajen Sitemap
ABOUT US
Company History
Contact Us
PIPELINE
Development Pipeline
BAL0891
SJ-600 Series
Pexa-Vec (JX-594)
JX-900 Series
TECHNOLOGY
GEEV ®
SOLVE ®
Scientific Publications
PARTNERSHIP
Global Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
ENG
|
KOR
ENG
ENG
KOR
Targeting, Attacking, and Eradicating Cancers®
TOP
IR/PR
ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
IR/PR
SillaJen Biotherapeutics
Publications & News
Publications & News
Financials
IR Inquiries
Publications & News
게시판
Total
31
. ˙
2
/
4
Page
Enter search terms
Run search button
21
SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy
2018-02-23
20
Cancer-Killing Virus Acts by Alerting Immune System
2018-02-13
19
SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies
2018-01-22
18
SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's Pexa-Vec Oncolytic Immunotherapy
2017-08-17
17
SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
2017-07-25
16
SillaJen teams up with Regeneron to combat kidney cancer
2017-05-10
15
Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer
2017-05-08
14
Enrollment of the First European Patient in Multinational Phase 3 Trial
2017-04-24
13
Issuance of Two Australian Patents
2017-03-02
12
SillaJen IR Letter (2017.01)
2017-01-03
1
2
3
4
Targeting, Attacking, and Eradicating Cancers®
